In inflamed joints, dysregulated RANKL signaling likely plays a major role in driving pathological osteoclast differentiation (4–6), and its neutralizing mAb, Denosumab, has become an approved therapeutic (50) that prevents bone loss in RA (51). This evidence concerns the gene TNFSF11 and rheumatoid arthritis.